Andrew J. Dimond, David S. Krantz, Andrew J. Waters, Romano Endrighi, Stephen S. Gottlieb

Similar documents
SOCIAL SUPPORT AND HEART FAILURE: DIFFERING EFFECTS BY RACE. Andrea Weiss

PSYCHOSOCIAL PREDICTORS OF ADVERSE EVENTS IN HEART FAILURE: THE UTILITY OF MULTIPLE MEASURES. Samantha L. Wronski

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

ANGER, HOSTILITY, AND RE-HOSPITALIZATIONS IN PATIENTS WITH HEART FAILURE. Felicia Keith

Psychological Stress and Disease: Implications for the Gulf Oil Spill. Sheldon Cohen, PhD Carnegie Mellon University

Nitrate s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction (NEAT) A Randomized Clinical Trial

Health Status after Transcatheter Mitral- Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial

CRITICALLY APPRAISED PAPER (CAP)

Depression, Anxiety, and the Decline of Physical Functioning over 6 Months in Patients with Heart Failure

Supplementary Online Content

SUPPLEMENTAL MATERIAL. Supplemental Methods. Duke CAD Index

Physical Activity, Aging and Well-Being

Qamar J. Khan Bruce F. Kimler Pavan S. Reddy Priyanka Sharma Jennifer R. Klemp Carol J. Fabian

The Role of Exercise in Management of Patients with Heart Failure

Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF)

Patient-Reported Outcomes: A Critical Insight into the Impact of Therapy

History and Current State of PROs. Disclosures

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

CRITICALLY APPRAISED PAPER (CAP)

Tiny Jaarsma Linköping University No conflict of interest

Cancer Patients Interest and Preferences for an Inpatient Smoking Cessation Program (SCP)

Biomarkers in the Assessment of Congestive Heart Failure

WHAT IS ADVANCED HEART FAILURE? James C. Fang, MD, FACC Professor and Chief Cardiovascular Division University of Utah School of Medicine

LIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:

Mindfulness as a Mediator of Psychological Wellbeing in a Stress Reduction Intervention for Cancer Patients - a randomized study

Know Your Number Aggregate Report Single Analysis Compared to National Averages

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

04 July 2016 ISA Uppsala, Sweden

Disparities in Transplantation Caution: Life is not fair.

Mario Kinsella MD FAASM 10/5/2016

Avoidant Coping Moderates the Association between Anxiety and Physical Functioning in Patients with Chronic Heart Failure

Stress Reactions and. Depression After. Cardiovascular Events

Synopsis. Study title. Investigational Product Indication Design of clinical trial. Number of trial sites Duration of clinical trial / Timetable

CRITICALLY APPRAISED PAPER (CAP)

Journal of the COPD Foundation

Follow-up of the CUPID Gene Therapy Studies A Roadmap for Enhancement of Myocardial Metabolism and Viability Roger J. Hajjar, MD

Summary ID# Clinical Study Summary: Study B4Z-MC-LYBX

Does quality of life predict morbidity or mortality in patients with atrial fibrillation (AF)?

Takotsubo Cardiomyopathy

CHAPTER - III METHODOLOGY

Heart failure (HF) is a complex clinical syndrome that results in the. impairment of the heart s ability to fill or to pump out blood.

OVER the past three decades, there has been an effort to

Family-centered Stress Management for Childhood Cancer: A Multimodal Intervention for Children Newly Diagnosed with Cancer and their Families

Charles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT

The REDUCE LAP Heart Failure Trial. David M Kaye MD, PhD on behalf of the REDUCE LAP HF Investigators

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Douglas L. Mann, Randall J. Lee, Andrew J.S. Coats, Gheorghe Neagoe, Dinu Dragomir, on behalf of the AUGMENT- HF Inves=gators

ASSOCIATIONS BETWEEN SELF-RATED HEALTH AND PERSONALITY

The State Trait Anger Expression Inventory (STAXI)

Short and Long Term Effects of Psychosocial Factors on the Outcome of Coronary Artery Bypass Surgery

Comorbidities in Heart Failure: Iron Deficiency. Ammar Chaudhary, MBChB, FRCPC King Faisal Specialist Hospital and Research Centre - Jeddah

Creating Devices for Personalized Health Monitoring: Cardiovascular Monitoring Case Studies

Iron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016

BACPR -Annual Conference London 2017

The Tapestry of Chronic Pelvic Pain: Hysteria vs. Hysterectomy

Incidence, Predictors, and Outcomes of Prosthesis-Patient Mismatch in 62,125 TAVR Patients. An STS/ACC TVT Registry Report

Interpersonal Conflict & Role Transitions Predict Poor Adherence to Aspirin after Acute Coronary Syndromes

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Endpoints in Heart Failure Clinical Trials: Challenges and Potential Resolutions

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

ESC CONGRESS Munich, Germany, August. Compliance to a Cardiac Rehabilitation Program: what are the benefits and impact on prognosis?

Race Original cohort Clean cohort HR 95%CI P HR 95%CI P. <8.5 White Black

Personal Well-being Among Medical Students: Findings from a Pilot Survey

Health literacy is associated with patients adherence-related knowledge and motivation, but not adherence or clinical outcomes

Presented by Nicola Straiton (PhD Candidate) Sydney Nursing School. The University of Sydney Page 1

Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age

Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS

Summary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ

Hypertension, Remodelling and Novel Biomarkers in African Subjects

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD

Evidence of Baroreflex Activation Therapy s Mechanism of Action

Sleep Apnea and Heart Failure

Looking Toward State Health Assessment.

Psychosocial factors of work ability among people with chronic cardiovascular diseases

Depressive Symptom Dimensions and Cardiovascular Prognosis among Women with Suspected Myocardial Ischemia

Wellness Coaching for People with Prediabetes

Catheter ABlation vs ANtiarrhythmic Drug Therapy in Atrial Fibrillation (CABANA) Trial

Diabetes and Heart Failure

The Integrative Pain Management Program: A Pilot Clinic Serving High-Risk Primary Care Patients with Chronic Pain

Supplementary Online Content

ARIC Manuscript Proposal #2099. PC Reviewed: 3/12/13 Status: A Priority: 2 SC Reviewed: Status: Priority:

Supplementary Online Content

End of Life Care in IJN Our journey. Dato Dr. David Chew Soon Ping Consultant Cardiologist National Heart Institute Malaysia

Iron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD

Predictor Value Cytokines for Recurrence of. Arrhythmia in Patients with Coronary Heart. Disease Combined Hypertension and Persistent

PSYCHOSOCIAL EVALUATION AND TREATMENT IN CHRONIC RESPIRATORY DISEASES

Reducing Hospital Readmissions and Increasing Time to Hospital Readmission in Blacks with Heart Failure

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials?

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.

The RealiseAF registry:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

High Risk OSA n = 5,359

CRITICALLY APPRAISED PAPER (CAP)

SUMMARY 8 CONCLUSIONS

Differences in Social 1. Running head: DIFFERENCES IN SOCIAL SUPPORT AS A RISK FACTOR

Stress and the Heart. Kim A. Poli MD, FACC Assistant Professor of Medicine Division of Cardiology, Albany Medical Center

Supplement DS1 Search strategy. EMBASE Search Strategy

LCD L B-type Natriuretic Peptide (BNP) Assays

Transcription:

Andrew J. Dimond, David S. Krantz, Andrew J. Waters, Romano Endrighi, Stephen S. Gottlieb Uniformed Services University, Bethesda MD and University of Maryland Hospital, Baltimore MD

Heart Failure Serious chronic condition Characterized by fatigue, breathlessness, and fluid build-up Exacerbations and remissions Repeated hospitalizations, up to 35% within 30 days Fluctuations in symptoms Medical/behavioral predictors of worsening include: Poor medication compliance Hypertensive episodes Coronary heart disease

HF Measurement Measures of HF worsening: Self-report of HF symptoms (e.g., shortness of breath, fatigue) Biomarkers (e.g., inflammatory markers, BNP) Functional status (e.g., activities of daily living, Six- Minute Walk Test) Hospitalizations for HF-related clinical events

Anger State anger: an acute emotional state, varying in intensity Trait anger: a stable disposition to experience state anger Trait anger is associated with the development of CHD and worsened CHD prognosis (Chida & Steptoe, 2009) Acute anger episodes important as triggering (i.e., precipitating) factor Incidence of ACS or MI increased between 2.4-7.3 fold within 2 hours after an anger outburst (Mostofsky et al., 2014) Few studies of short-term anger as a possible precipitating factor in HF

Acute and Chronic Stress Recent findings in our lab demonstrated relationships between chronic and acutely elevated perceived stress and HF worsening When stress was assessed repeatedly over 3 month period (Endrighi et al., 2015) Adverse events: predicted by chronically elevated stress Functional status: predicted by bi-weekly fluctuations in stress Symptoms: predicted by both chronic stress and fluctuations in stress

Study Purpose 1. Determine effects of acute anger on short-term (2 week) changes in HF severity using 3 measures of HF outcomes 2. Compare effects of state anger to those of perceived stress

Methods Project BETRHEART 150 study participants recruited from: Heart Failure Clinic at the University of Maryland Hospital in Baltimore, MD Eligibility: Current diagnosis of heart failure and > 21 years of age Baseline interview included measures for: Demographics Medical status Psychosocial variables (e.g., chronic and acute anger, perceived stress, depression, social support, etc.)

Methods Measurement of stress Perceived Stress Scale (PSS; Cohen et al., 1983) Measurement of state anger State Trait Anger Expression Inventory-II (STAXI-II; Spielberger et al., 1985) Measurement of perceived symptoms Kansas City Cardiomyopathy Questionnaire (KCCQ) Summary Score: Measures physical symptoms, social interference, selfefficacy, and quality of life (Green et al., 2000) Measurement of functional status Six-Minute Walk Test (6-MWT) Adverse Events: Hospitalizations for cardiac causes (including HF) or participant death

Clinic Assessment: Baseline (PSS, Anger, KCCQ, 6MWT) n = 144 *At each interview, patients scoring in the top & bottom 30% of PSS were scheduled for up to 5 clinic visits 2 Week (PSS, Anger, Adverse Events) n = 137 4 Week (PSS, Anger, Adverse Events) n = 129 6 Week (PSS, Anger, Adverse Events) n = 125 8 Week (PSS, Anger, Adverse Events) n = 125 10 Week (PSS, Anger, Adverse Events) n = 126 *Clinic (KCCQ & 6MWT) n = 81 Clinic (KCCQ & 6MWT) n = 79 Clinic (KCCQ & 6MWT) n = 73 Clinic (KCCQ & 6MWT) n = 72 Clinic (KCCQ & 6MWT) n = 83 Clinic Assessment: 3 Month (PSS, Anger, Adverse Events, KCCQ, 6MWT) n = 126 9 Month (Adverse Events) n = 96

Data Analytic Plan Linear mixed models (SAS) prospective associations modelled as: Mean IV (aggregated over all assessments); Do patients with higher Mean IV scores have worse outcome? (a between-subject level analysis) Deviation IV (difference between IV score at each assessment and Mean IV ); At assessments in which patients have a higher IV score compared to their average do they have a worse subsequent outcome? (a within-subject level analysis)

Results Patient characteristics Variable Mean ± SD or % Age (yrs) 57.51± 11.52 Male sex (%) 77.0 BMI (kg/m 2 ) 30.87 ± 7.50 NYHA class II (%) III (%) IV (%) 54.9 43.1 2.1 Hypertension yes (%) no (%) Income $ <15k (%) 15-30k (%) 30-70k (%) >70k (%) Race Caucasian (%) African American (%) American Indian (%) 79.2 20.8 34.3 26.6 30.1 9.1 29.2 70.1 0.7

State Anger and Stress Associations Outcome Variable Assessment Level State Anger Stress Adverse Events Between-subjects Within-subjects 0.04-0.02 0.10 0.00 KCCQ (Symptoms) Between-subjects Within-subjects -1.23-0.10-1.59-0.25 6-MWT (Functional status) Between-subjects Within-subjects -0.06-2.55 p < 0.05-2.75-3.26

State Anger and Stress Associations Outcome Variable Assessment Level State Anger Stress Adverse Events Between-subjects Within-subjects 0.04-0.02 0.10 0.00 KCCQ (Symptoms) Between-subjects Within-subjects -1.23-0.10-1.59-0.25 6-MWT (Functional status) Between-subjects Within-subjects -0.06-2.55 p < 0.05-2.75-3.26

State Anger and Stress Associations Outcome Variable Assessment Level State Anger Stress Adverse Events Between-subjects Within-subjects 0.04-0.02 0.10 0.00 KCCQ (Symptoms) Between-subjects Within-subjects -1.23-0.10-1.59-0.25 6-MWT (Functional status) Between-subjects Within-subjects -0.06-2.55 p < 0.05-2.75-3.26 Endrighi et al., 2015

Covariate Associations Outcome Variable Predictor (Mean IV) Between- Subjects Within- Subjects Adverse Events State anger controlling for stress Stress controlling for state anger 0.04 0.12 0.03 0.10 KCCQ (Symptoms) State anger controlling for stress Stress controlling for state anger -0.07-1.57-0.05-0.24 6-MWT (Functional status) State anger controlling for stress Stress controlling for state anger 3.29-3.79-1.83-2.94

Covariate Associations Outcome Variable Predictor (Mean IV) Between- Subjects Within- Subjects Adverse Events State anger controlling for stress Stress controlling for state anger 0.04 0.12 0.03 0.10 KCCQ (Symptoms) State anger controlling for stress Stress controlling for state anger -0.07-1.57-0.05-0.24 6-MWT (Functional status) State anger controlling for stress Stress controlling for state anger 3.29-3.79-1.83-2.94

Covariate Associations Outcome Variable Predictor (Mean IV) Between- Subjects Within- Subjects Adverse Events State anger controlling for stress Stress controlling for state anger 0.04 0.12 0.03 0.10 KCCQ (Symptoms) State anger controlling for stress Stress controlling for state anger -0.07-1.57-0.05-0.24 6-MWT (Functional status) State anger controlling for stress Stress controlling for state anger 3.29-3.79-1.83-2.94

Results Summary Greater mean state anger associated with worse symptoms and sharp increases in state anger associated with reduced functional status When controlling for stress, state anger was not associated with any HF measures When controlling for state anger, chronic stress was related to adverse events, acute stress was related to functional status, and both were related to symptoms

Study Limitations Generalizability to other populations; AA and low SES Only top and bottom thirds on stress performed 6- MWT and completed KCCQ on bi-weekly basis Two week assessment period may be too long to measure effects of acute anger

Conclusion State anger is associated with short-term fluctuations in functional status and mean worsened symptom status in HF patients Perceived stress is more strongly associated with these endpoints and adverse events than state anger After controlling for stress, state anger was not associated with short-term HF outcomes Effects of state anger may operate through its associations with perceived stress Mechanisms for these associations may involve physiological changes associated with perceived stress and state anger, and/or effects of stress and emotion on psychological (e.g., depression) or behavioral factors (e.g., compliance with medications), etc.

Questions